Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Pfeffer

Showing results (681-690 of 754) with videos related to

Pageof 76
Sort By:
Arxiv|December 19, 2025
Monitoring Deployed AI Systems in Health CareTimothy Keyes, Alison Callahan, Abby S Pandya, et al.
NEJM Catalyst Innovations in Care Delivery|July 8, 2026
Why and How to Monitor Deployed AI Systems in Health CareTimothy Keyes, Alison Callahan, Abby S Pandya, et al.
JACC. Heart Failure|July 11, 2021
Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF: The PARAGON-HF TrialMauro Gori, Michele Senni, Brian Claggett, et al.
European Journal of Heart Failure|March 27, 2020
Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndromeSung-Hee Shin, Brian Claggett, Marc A Pfeffer, et al.
European Heart Journal|April 21, 2017
Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trialsAzmil H Abdul-Rahim, Ana-Cristina Perez, Rachael L MacIsaac, et al.
JAMA|July 9, 2004
Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trialMichael A Blazing, James A de Lemos, Harvey D White, et al.
Circulation|September 1, 2024
Therapeutic Effects of Heart Failure Medical Therapies on Standardized Kidney Outcomes: Comprehensive Individual Participant-Level Analysis of 6 Randomized Clinical TrialsJawad H Butt, John J V McMurray, Brian L Claggett, et al.
Circulation. Heart Failure|August 15, 2014
Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) TrialAmil M Shah, Brian Claggett, Nancy K Sweitzer, et al.
European Heart Journal|July 20, 2022
Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trialJean Claude Tardif, Marc A Pfeffer, Simon Kouz, et al.
Diabetes, Obesity & Metabolism|January 24, 2019
Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney diseaseDavid M Charytan, Scott D Solomon, Peter Ivanovich, et al.
Pageof 76

Showing results (681-690 of 754) with videos related to

Sort By:
Pageof 76
Arxiv|December 19, 2025
Monitoring Deployed AI Systems in Health CareTimothy Keyes, Alison Callahan, Abby S Pandya, et al.
NEJM Catalyst Innovations in Care Delivery|July 8, 2026
Why and How to Monitor Deployed AI Systems in Health CareTimothy Keyes, Alison Callahan, Abby S Pandya, et al.
JACC. Heart Failure|July 11, 2021
Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF: The PARAGON-HF TrialMauro Gori, Michele Senni, Brian Claggett, et al.
European Journal of Heart Failure|March 27, 2020
Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndromeSung-Hee Shin, Brian Claggett, Marc A Pfeffer, et al.
European Heart Journal|April 21, 2017
Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trialsAzmil H Abdul-Rahim, Ana-Cristina Perez, Rachael L MacIsaac, et al.
JAMA|July 9, 2004
Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trialMichael A Blazing, James A de Lemos, Harvey D White, et al.
Circulation|September 1, 2024
Therapeutic Effects of Heart Failure Medical Therapies on Standardized Kidney Outcomes: Comprehensive Individual Participant-Level Analysis of 6 Randomized Clinical TrialsJawad H Butt, John J V McMurray, Brian L Claggett, et al.
Circulation. Heart Failure|August 15, 2014
Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) TrialAmil M Shah, Brian Claggett, Nancy K Sweitzer, et al.
European Heart Journal|July 20, 2022
Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trialJean Claude Tardif, Marc A Pfeffer, Simon Kouz, et al.
Diabetes, Obesity & Metabolism|January 24, 2019
Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney diseaseDavid M Charytan, Scott D Solomon, Peter Ivanovich, et al.
Pageof 76